Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis.
Large granular lymphocytic (LGL) leukaemia and chronic natural killer cell lymphocytosis (CNKL) are chronic indolent disorders often associated with neutropenia and constitutional symptoms. Severe anaemia occurs in about 20% of patients and is currently treated with corticosteroids followed by oral cyclophosphamide in non-responders. 30% of patients fail initial measures, and salvage therapy is inadequate. We describe three transfusion-dependent patients (two with T-LGL leukaemia, one with CNKL) refractory to corticosteroids, cyclophosphamide, and in one case fludarabine. Cyclosporine A (CSA) initiation resulted in prompt transfusion-independence and was well tolerated in all patients, making it an attractive alternative therapy for this disorder.
Bible
K C
KC
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Tefferi
A
A
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007694:Killer Cells, Natural / Q000473:pathology; D015458:Leukemia, T-Cell / Q000150:complications*; D008218:Lymphocytosis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D016572:Cyclosporine